GSK to withdraw blood cancer drug Blenrep from US market
GSK said access to Blenrep in other countries where it is marketed is unaffected, including across the European Union.
London: GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, representing the latest in a series of setbacks for the British drugmaker's oncology business.
The company had said this month that Blenrep failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the U.S. Food and Drug Administration (FDA).
On Tuesday GSK said it has begun the process to withdraw Blenrep's marketing authorisation in the country but will continue trial programmes for the drug, adding that some patients will have the option to enrol for continued access to the treatment.
"We will continue the DREAMM clinical trial programme and work with the U.S. FDA on a path forward for this important treatment option for patients with multiple myeloma," GSK Chief Medical Officer Sabine Luik said in a statement.
GSK said access to Blenrep in other countries where it is marketed is unaffected, including across the European Union. The company is still discussing the latest clinical data with EU health authorities, a GSK official said.
The drug was given speedy approval by the FDA in 2020 and approved for patients with relapsed or refractory multiple myeloma who received at least four previous therapies.
Last year the drug achieved 89 million pounds ($105 million) in global sales, about two-thirds of which was from the United States.
Oncology is a key area of focus for GSK as a standalone prescription medicine and vaccine business, but the company suffered another blow this month after it had to limit the use of its ovarian cancer drug Zejula in the United States.
Blenrep belongs to a category of treatments called antibody-drug conjugates, which are engineered antibodies that bind to tumour cells and then release cell-killing chemicals
Read also: GSK Pharma shuts its consumer trade channel, impacting around 200 employees
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.